封面
市场调查报告书
商品编码
1482460

微量残存疾病检测市场:按技术、按应用、按最终用户、按地区

Minimal Residual Disease Testing Market, By Technology (Flow Cytometry, Polymerase chain reaction, and Next generation sequencing), By Application, By End User, By Geography

出版日期: | 出版商: Coherent Market Insights | 英文 173 Pages | 商品交期: 2-3个工作天内

价格
简介目录

微量残存疾病检测市场预计到2024年将达到23.1亿美元,预计到2031年将达到49.7亿美元,2024年至2031年的复合年增长率为11.6%。

报告范围 报告详情
基准年 2023年 2024年市场规模 23.1亿美元
实际资料 2019年至2023年 预测期 从2024年到2031年
预测 2024-2031 年复合年增长率: 11.60% 2031 年的预测值 49.7亿美元
图:2024 年按地区分類的微量残存疾病检测市场占有率(%)
微小残留疾病检测市场-IMG1

微量残存疾病(MRD) 检测可检测初始治疗后可能残留在体内的少量癌细胞。 MRD 检测是血液学家和肿瘤学家监测治疗效果和预测患者结果的重要工具。 MRD 检测使医生能够比其他方法更早识别疾病復发风险较高的患者。这将有助于确定是否需要额外的治疗或更密切的监测。多种技术已被用于高灵敏度检测 MRD,包括多参数流式细胞技术、对偶基因特异性特异性寡核苷酸定量 PCR 和次世代定序。随着MRD检测在各类血癌的广泛应用和技术的改进,预计未来几年市场将显着成长。

市场动态:

全球微量残存疾病检测市场的推动因素包括血癌盛行率上升、治疗监测中 MRD 检测的日益采用以及医生意识的提高。然而,缺乏熟练的专业人员、检测方法的高指数化以及某些地区的报销问题正在限制市场的成长。该公司正在推出各种具有更高灵敏度和自动化平台的新产品,这是一个重大商机。例如,个人化治疗和液态切片技术都是新领域。公司和研究机构之间的合作研究也支持市场向新地区的扩张。儘管 COVID-19 大流行对医疗保健资源的影响是一个挑战,远端医疗和家庭样本采集正在支持当前情况下 MRD 监测的连续性。

本研究的主要特点

  • 本报告对全球微量残存疾病检测市场进行了详细分析,并列出了以2023年为基准年的预测期(2024-2031年)的市场规模和年复合成长率(CAGR%) 。
  • 它说明了各个细分市场的潜在收益成长机会,并为该市场提供了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
  • 本报告根据公司亮点、产品系列、主要亮点、财务表现和策略等参数,介绍了全球微量残存疾病检测市场的主要企业。
  • 该报告的见解使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
  • 全球微量残存疾病检测市场迎合了该行业的各种相关人员,如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 透过用于分析全球微量残存疾病检测市场的各种策略矩阵,将有助于相关人员做出决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map(COM)

第三章市场动态、法规及趋势分析

  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
  • 影响分析
  • 市场趋势
  • 流行病学
  • 最近的趋势
  • 收购和合作场景
  • 资金筹措和投资
  • PEST分析
  • 波特的分析

第四章 全球微量残存疾病检测市场:COVID-19 大流行的影响

  • 整体影响
  • 政府倡议
  • COVID-19 对市场的影响

第五章 全球微量残存疾病检测市场:依技术分类,2019-2031

  • 流式细胞技术
  • 聚合酵素链锁反应(PCR)
  • 其他的

第六章 全球微量残存疾病检测市场:依应用分类,2019-2031

  • 淋巴瘤
  • 固态肿瘤
  • 其他的

第七章 全球微量残存疾病检测市场:依最终使用者分类,2019-2031 年

  • 医院
  • 诊所
  • 研究室
  • 其他的

第八章 全球微量残存疾病检测市场:依地区划分,2019-2031

第9章 竞争格局

  • 公司简介
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd
    • Guardant Health, Inc.
    • Adaptive Biotechnologies
    • Invitae Corporation
    • ASURAGEN, INC.
    • Invivoscribe, Inc.
    • Laboratory Corporation of America Holdings
    • Natera, Inc.
    • Sysmex Inostics, Inc.
    • Amgen Inc.
    • FOUNDATION MEDICINE, INC.
    • Sebia
    • Myriad Genetics, Inc.

第10章分析师的观点

  • 分析师观点
  • 一致的机会图

第十一章 参考文献与调查方法

  • 参考
  • 调查方法
简介目录
Product Code: CMI6888

The minimal residual disease testing market is estimated to be valued at USD 2.31 Bn in 2024 and is expected to reach USD 4.97 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 11.6% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 2.31 Bn
Historical Data for: 2019 To 2023 Forecast Period: 2024 To 2031
Forecast Period 2024 to 2031 CAGR: 11.60% 2031 Value Projection: US$ 4.97 Bn
Figure. Minimal Residual Disease Testing Market Share (%), By Region 2024
Minimal Residual Disease Testing Market - IMG1

Minimal Residual Disease (MRD) testing involves detecting tiny amounts of residual cancer cells that may remain in the body after initial treatment. It is an important tool for both hematologists and oncologists to monitor treatment response and predict outcomes for patients. MRD testing allows physicians to identify those who may be at higher risk of disease relapse earlier than other methods. This helps determine if additional therapies or closer monitoring is needed. Several technologies such as multiparameter flow cytometry, allele-specific oligonucleotide quantitative PCR, and next generation sequencing are used to detect MRD with high sensitivity. With growing applications of MRD testing across different types of blood cancers and improving technologies, the market is expected to witness significant growth in the coming years.

Market Dynamics:

The global minimal residual disease testing market is driven by rising incidence of hematological cancers, increasing adoption of MRD testing in treatment monitoring, and growing awareness among physicians. However, lack of skilled professionals, high index of testing methods, and reimbursement issues in some regions are restraining the market growth. Various new product launches by players with improved sensitivity and automated platforms present key opportunities. For instance, personalized therapy and liquid biopsy techniques are emerging areas. Collaborations between companies and research institutes are also supporting market expansion into new geographies. The effects of the COVID-19 pandemic on healthcare resources is a challenge, though telemedicine and home-based sample collection aid continuity of MRD monitoring in current scenario.

Key Features of the Study:

  • This report provides an in-depth analysis of the global minimal residual disease testing market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global minimal residual disease testing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study includes Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Adaptive Biotechnologies, Invitae Corporation, ASURAGEN, INC., Invivoscribe, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Sysmex Inostics, Inc., Amgen Inc., FOUNDATION MEDICINE, INC., Sebia, and Myriad Genetics, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global minimal residual disease testing market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global minimal residual disease testing market

Detailed Segmentation-

  • Technology:
    • Flow Cytometry
    • Polymerase chain reaction (PCR)
    • Next generation sequencing
  • Application:
    • Lymphoma
    • Solid Tumors
    • Others
  • End User:
    • Hospitals
    • Clinics
    • Research Laboratories
    • Others
  • Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Bio-Rad Laboratories, Inc.
    • Hoffmann-La Roche Ltd
    • Guardant Health, Inc.
    • Adaptive Biotechnologies
    • Invitae Corporation
    • ASURAGEN, INC.
    • Invivoscribe, Inc.
    • Laboratory Corporation of America Holdings
    • Natera, Inc.
    • Sysmex Inostics, Inc.
    • Amgen Inc.
    • FOUNDATION MEDICINE, INC.
    • Sebia
    • Myriad Genetics, Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Technology
    • Market Snapshot, By Application
    • Market Snapshot, By End User
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Epidemiology
  • Recent Developments
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Minimal Residual Disease Testing Market- Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global Minimal Residual Disease Testing Market, By Technology, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Flow Cytometry
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Polymerase chain reaction (PCR)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Minimal Residual Disease Testing Market, By Application, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Lymphoma
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Solid Tumors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Minimal Residual Disease Testing Market, By End User, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospitals
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Clinics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Research Laboratories
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Minimal Residual Disease Testing Market, By Region, 2019 - 2031, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Regions, 2020-2031
    • Regional Trends
      • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.S.
      • Canada
      • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
      • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
      • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
      • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • GCC
      • Israel
      • Rest of Middle East
      • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Company Profiles
    • Bio-Rad Laboratories, Inc.*
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • F. Hoffmann-La Roche Ltd
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Guardant Health, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Adaptive Biotechnologies
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Invitae Corporation
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • ASURAGEN, INC.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Invivoscribe, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Laboratory Corporation of America Holdings
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Natera, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sysmex Inostics, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Amgen Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • FOUNDATION MEDICINE, INC.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sebia
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Myriad Genetics, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies

10. Analyst View

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact